Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mallinckrodt Nellcor Puritan Bennett Line Breathes New Air Into Tyco

This article was originally published in The Gray Sheet

Executive Summary

Tyco International's decision to account for its $4.2 bil. stock acquisition of Mallinckrodt as a purchase rather than a pooling-of-interests transaction, gives the company the flexibility to divest Mallinckrodt's imaging drugs and bulk pharmaceuticals businesses and concentrate on the fast-growing respiratory products division.

You may also be interested in...



Tyco Urology Franchise Leaps Ahead With $3.2 Bil. Bard Acquisition

Tyco International will increase its total health care sales to about $7.6 bil. annually through acquisition of C.R. Bard for approximately $3.2 bil. in stock. Valued at nearly three times Bard's 2000 sales of $1.1 bil., the definitive agreement was announced May 30.

Tyco Urology Franchise Leaps Ahead With $3.2 Bil. Bard Acquisition

Tyco International will increase its total health care sales to about $7.6 bil. annually through acquisition of C.R. Bard for approximately $3.2 bil. in stock. Valued at nearly three times Bard's 2000 sales of $1.1 bil., the definitive agreement was announced May 30.

Tyco Takes Steps To Add InnerDyne Surgical Access Line Via $180 Mil. Bid

Tyco International's purchase of InnerDyne for $180 mil. would give the company access to the Sunnyvale, Calif. firm's Step line of minimally invasive access products for laparoscopic surgery.

Related Content

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel